Tags

Type your tag names separated by a space and hit enter

Evidence-based medicine and osteoporosis: a comparison of fracture risk reduction data from osteoporosis randomised clinical trials.
Int J Clin Pract 1999; 53(2):122-9IJ

Abstract

The goal of osteoporosis therapy is to prevent fractures, and many therapies are available for this disease. Regarding proven fracture benefit, however, the quality of the randomised clinical trial evidence varies substantially among therapies. The purpose of this paper is, therefore, to review the published osteoporosis randomised clinical trial literature and to assess the quality of the evidence. Although more than 35 randomised trials for different therapies were reviewed, only alendronate and vitamin D plus calcium have clearly demonstrated a fracture benefit, with alendronate providing the greatest relative risk reduction. Quality clinical trial fracture data for calcitonin, etidronate, fluoride, hormone replacement therapy, parathyroid hormone, calcitriol (and other vitamin D preparations), vitamin D and calcium monotherapy, and selective oestrogen receptor modulators are either lacking or inconclusive or published only as abstracts.

Authors+Show Affiliations

Department of Rheumatology and Bone Diseases, Edouard Herriot Hospital, Lyon, France.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

10344048

Citation

Meunier, P J.. "Evidence-based Medicine and Osteoporosis: a Comparison of Fracture Risk Reduction Data From Osteoporosis Randomised Clinical Trials." International Journal of Clinical Practice, vol. 53, no. 2, 1999, pp. 122-9.
Meunier PJ. Evidence-based medicine and osteoporosis: a comparison of fracture risk reduction data from osteoporosis randomised clinical trials. Int J Clin Pract. 1999;53(2):122-9.
Meunier, P. J. (1999). Evidence-based medicine and osteoporosis: a comparison of fracture risk reduction data from osteoporosis randomised clinical trials. International Journal of Clinical Practice, 53(2), pp. 122-9.
Meunier PJ. Evidence-based Medicine and Osteoporosis: a Comparison of Fracture Risk Reduction Data From Osteoporosis Randomised Clinical Trials. Int J Clin Pract. 1999;53(2):122-9. PubMed PMID: 10344048.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evidence-based medicine and osteoporosis: a comparison of fracture risk reduction data from osteoporosis randomised clinical trials. A1 - Meunier,P J, PY - 1999/5/27/pubmed PY - 1999/5/27/medline PY - 1999/5/27/entrez SP - 122 EP - 9 JF - International journal of clinical practice JO - Int. J. Clin. Pract. VL - 53 IS - 2 N2 - The goal of osteoporosis therapy is to prevent fractures, and many therapies are available for this disease. Regarding proven fracture benefit, however, the quality of the randomised clinical trial evidence varies substantially among therapies. The purpose of this paper is, therefore, to review the published osteoporosis randomised clinical trial literature and to assess the quality of the evidence. Although more than 35 randomised trials for different therapies were reviewed, only alendronate and vitamin D plus calcium have clearly demonstrated a fracture benefit, with alendronate providing the greatest relative risk reduction. Quality clinical trial fracture data for calcitonin, etidronate, fluoride, hormone replacement therapy, parathyroid hormone, calcitriol (and other vitamin D preparations), vitamin D and calcium monotherapy, and selective oestrogen receptor modulators are either lacking or inconclusive or published only as abstracts. SN - 1368-5031 UR - https://www.unboundmedicine.com/medline/citation/10344048/Evidence_based_medicine_and_osteoporosis:_a_comparison_of_fracture_risk_reduction_data_from_osteoporosis_randomised_clinical_trials_ L2 - http://www.diseaseinfosearch.org/result/9059 DB - PRIME DP - Unbound Medicine ER -